Phoenix, AZ— bioSyntagma, LLC, a developer of life science tools for single and multi-cell analysis announced today it has been has been awarded a National Science Foundation (NSF) Phase II Small Business Innovation Research (SBIR) grant of $735,139.
Upon completion of the Phase I SBIR, bioSyntagma successfully demonstrated feasibility of their technology, the LightStream FloCellTM, which visually maps genetic information across a tissue and correlates this information with molecular measurements in a high-throughput and automated fashion, with the ultimate goal of enabling personalized medicine. Phase II funding will be used to continue product development and launch commercialization.
bioSyntagma will produce their first beta instruments by implementing their technology into a high-throughput commercial product. They will hire additional staff to support development as well as create artificial intelligence algorithms to mine the data produced on these instruments. This will allow bioSyntagma to commercially launch their platform technology for discovery and implementation of precision medicines.
About the NSF’s Small Business Programs: America’s Seed Fund powered by NSF awards nearly $190 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.5 million in non-dilutive funds to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $7.5 billion that supports fundamental research and education across all fields of science and engineering. For more information, visit seedfund.nsf.gov.